Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR4 | P22455 | 16/20 | 0.68 |
| ▸ | FGFR1 | P11362 | 5/20 | 0.52 |
| ▸ | FGFR2 | P21802 | 5/20 | 0.52 |
| ▸ | FGFR3 | P22607 | 5/20 | 0.52 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.43 |
| ▸ | KDR | P35968 | 1/20 | 0.42 |
| ▸ | GSK3A | P49840 | 1/20 | 0.34 |
| ▸ | GSK3B | P49841 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3975638 | 0.85 | FGFR4 (0.75) | FGFR4FGFR1FGFR2FGFR3KDR | |
| SCHEMBL20734029 | 0.84 | FGFR4 (0.47) | FGFR4FGFR1FGFR2FGFR3KDR | |
| SCHEMBL15412943 | 0.81 | FGFR4 (1.00) | FGFR4FGFR1FGFR2FGFR3KDR | |
| SCHEMBL29388619 | 0.78 | FGFR4 (0.53) | FGFR4FGFR1FGFR2FGFR3CYP19A1 | |
| SCHEMBL22532554 | 0.78 | FGFR4 (0.53) | FGFR4FGFR1FGFR2FGFR3CYP19A1 | |
| SCHEMBL16071675 | 0.77 | FGFR4 (0.60) | FGFR4FGFR1FGFR2FGFR3KDR | |
| SCHEMBL28656646 | 0.76 | FGFR4 (0.50) | FGFR4FGFR1FGFR2FGFR3KDR | |
| SCHEMBL16071531 | 0.76 | FGFR4 (0.74) | FGFR4FGFR1FGFR2FGFR3KDR | |
| SCHEMBL28633170 | 0.72 | FGFR4 (0.64) | FGFR4FGFR1FGFR2FGFR3 | |
| SCHEMBL28734479 | 0.72 | FGFR4 (0.66) | FGFR4FGFR1FGFR2FGFR3KDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2019029541-A1 | FIBROBLAST GROWTH FACTOR RECEPTOR INHIBITOR AND USE THEREOF | 南京药捷安康生物科技有限公司 | 2019-02-14 | — | — | WO | disclosed |